


N-Cadherin Antibody / CDH2 / CD325 [clone 13A9] (V3390)

Catalog No.	Formulation	Size
V3390-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V3390-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V3390SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug


 [Citations \(27\)](#)

[Bulk quote request](#)


Species Reactivity	Human, Mouse
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	13A9
Purity	Protein G affinity chromatography
Buffer	1X PBS, pH 7.4
UniProt	P19022
Localization	Cytoplasmic
Applications	Flow Cytometry : 1-2ug/million cells Immunofluorescence : 1-2ug/ml Western Blot : 1-2ug/ml
Limitations	This N-Cadherin antibody is available for research use only.



Western blot testing of human brain lysate with N-Cadherin antibody. Predicted molecular weight ~100 kDa (unmodified), 125-140 kDa (modified).



SDS-PAGE Analysis of Purified, BSA-Free N-Cadherin Antibody (clone 13A9). Confirmation of Integrity and Purity of the Antibody.



Western blot testing of human heart tissue lysate with N-Cadherin antibody. Predicted molecular weight ~100 kDa (unmodified), 125-140 kDa (modified).

Description

Recognizes a protein of ~140 kDa, identified as N-Cadherin (NCAD), also known as CDH2 and CD325. NCAD is a member of the Cadherin superfamily, and consists of five extracellular repeats, a transmembrane domain and a cytoplasmic domain. NCAD/CD325 deficient mice die at day 10 of gestation and embryos display major heart defects and malformed neural tubes and somites. Consistent with this, the protein has been implicated in several aspects of cardiac development including the precardiac mesoderm, establishment of left-right symmetry and cardiac looping morphogenesis. Furthermore, it is normally involved in inducing cell cycle arrest and its expression is frequently deregulated in cancer cells. Studies have linked N-cadherin to cancer metastasis by showing the aggressive tumor cells had preferentially turned on N-cadherin as opposed to E- or P-cadherin.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the N-Cadherin antibody to be titrated up or down for optimal performance.

Immunogen

A human partial recombinant protein corresponding to the CDH2/NCAD cytoplasmic domain was used as the immunogen for this N-Cadherin antibody.

Storage

Store the N-Cadherin antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).